EMA considerations on COVID-19 vaccine approval - Scientific guideline

HumanCOVID-19Vaccines

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

This document provides guidance for developers of potential COVID-19 vaccines on the clinical evidence to include in marketing authorisation applications.

Keywords: COVID-19, SARS-CoV-2, vaccine, clinical requirements, clinical efficacy, clinical safety

Current version

EMA considerations on COVID-19 vaccine approval

Adopted Reference Number: EMA/592928/2020

English (EN) (205.33 KB - PDF)

First published: 19/11/2020

Document history

EMA considerations on COVID-19 vaccine approval

Adopted Reference Number: EMA/592928/2020

English (EN) (205.33 KB - PDF)

First published: 19/11/2020